MorphoSys (ETR:MOR) Shares Down 0.1%

MorphoSys AG (ETR:MOR) dropped 0.1% during trading on Wednesday . The company traded as low as €66.50 ($71.51) and last traded at €66.75 ($71.77). Approximately 106,985 shares traded hands during mid-day trading, a decline of 30% from the average daily volume of 153,687 shares. The stock had previously closed at €66.80 ($71.83).

MorphoSys Stock Performance

The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -12.07, a price-to-earnings-growth ratio of 0.06 and a beta of 0.60. The company has a current ratio of 3.08, a quick ratio of 3.49 and a debt-to-equity ratio of 3,454.18. The firm has a 50-day simple moving average of €66.73 and a two-hundred day simple moving average of €47.35.

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.